Genomic test to guide chemotherapy in young women with breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are premenopausal (still having periods or not yet through menopause)
- You are 35 years old or older
- Your breast cancer is hormone receptor positive and HER2 negative
- You had surgery for your breast cancer within the last 12 weeks
- You have either 1-3 positive lymph nodes or a tumor 5 cm or larger with no positive nodes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
This study uses tumor genetic testing to help plan more precise treatment for people with early high-risk breast cancer. You may be asked to give a recent tumor sample so researchers can match your cancer features with the best available options.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.